S&P 500   4,088.52 (+0.21%)
DOW   34,477.88 (-0.32%)
QQQ   294.04 (+0.23%)
AAPL   148.20 (+0.11%)
MSFT   253.50 (-0.64%)
META   119.00 (+0.76%)
GOOGL   100.93 (-0.06%)
AMZN   97.01 (+0.49%)
TSLA   197.88 (+1.63%)
NVDA   169.86 (+0.37%)
NIO   12.65 (-1.02%)
BABA   85.30 (-2.58%)
AMD   78.25 (+0.80%)
T   19.25 (-0.16%)
MU   57.66 (+0.02%)
CGC   3.70 (+2.21%)
F   14.02 (+0.86%)
DIS   98.15 (+0.29%)
AMC   7.29 (+0.83%)
PYPL   79.00 (+0.75%)
PFE   50.20 (+0.14%)
NFLX   304.73 (-0.26%)
S&P 500   4,088.52 (+0.21%)
DOW   34,477.88 (-0.32%)
QQQ   294.04 (+0.23%)
AAPL   148.20 (+0.11%)
MSFT   253.50 (-0.64%)
META   119.00 (+0.76%)
GOOGL   100.93 (-0.06%)
AMZN   97.01 (+0.49%)
TSLA   197.88 (+1.63%)
NVDA   169.86 (+0.37%)
NIO   12.65 (-1.02%)
BABA   85.30 (-2.58%)
AMD   78.25 (+0.80%)
T   19.25 (-0.16%)
MU   57.66 (+0.02%)
CGC   3.70 (+2.21%)
F   14.02 (+0.86%)
DIS   98.15 (+0.29%)
AMC   7.29 (+0.83%)
PYPL   79.00 (+0.75%)
PFE   50.20 (+0.14%)
NFLX   304.73 (-0.26%)
S&P 500   4,088.52 (+0.21%)
DOW   34,477.88 (-0.32%)
QQQ   294.04 (+0.23%)
AAPL   148.20 (+0.11%)
MSFT   253.50 (-0.64%)
META   119.00 (+0.76%)
GOOGL   100.93 (-0.06%)
AMZN   97.01 (+0.49%)
TSLA   197.88 (+1.63%)
NVDA   169.86 (+0.37%)
NIO   12.65 (-1.02%)
BABA   85.30 (-2.58%)
AMD   78.25 (+0.80%)
T   19.25 (-0.16%)
MU   57.66 (+0.02%)
CGC   3.70 (+2.21%)
F   14.02 (+0.86%)
DIS   98.15 (+0.29%)
AMC   7.29 (+0.83%)
PYPL   79.00 (+0.75%)
PFE   50.20 (+0.14%)
NFLX   304.73 (-0.26%)
S&P 500   4,088.52 (+0.21%)
DOW   34,477.88 (-0.32%)
QQQ   294.04 (+0.23%)
AAPL   148.20 (+0.11%)
MSFT   253.50 (-0.64%)
META   119.00 (+0.76%)
GOOGL   100.93 (-0.06%)
AMZN   97.01 (+0.49%)
TSLA   197.88 (+1.63%)
NVDA   169.86 (+0.37%)
NIO   12.65 (-1.02%)
BABA   85.30 (-2.58%)
AMD   78.25 (+0.80%)
T   19.25 (-0.16%)
MU   57.66 (+0.02%)
CGC   3.70 (+2.21%)
F   14.02 (+0.86%)
DIS   98.15 (+0.29%)
AMC   7.29 (+0.83%)
PYPL   79.00 (+0.75%)
PFE   50.20 (+0.14%)
NFLX   304.73 (-0.26%)
NASDAQ:ATAI

Atai Life Sciences - ATAI Stock Forecast, Price & News

$3.53
+0.37 (+11.71%)
(As of 11/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.16
$3.55
50-Day Range
$2.63
$3.53
52-Week Range
$2.60
$11.92
Volume
2.47 million shs
Average Volume
1.15 million shs
Market Capitalization
$585.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.83

Atai Life Sciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
602.5% Upside
$24.80 Price Target
Short Interest
Healthy
3.89% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.77mentions of Atai Life Sciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.94) to ($1.03) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

584th out of 1,043 stocks

Pharmaceutical Preparations Industry

278th out of 510 stocks

ATAI stock logo

About Atai Life Sciences (NASDAQ:ATAI) Stock

Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.

Receive ATAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atai Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

ATAI Stock News Headlines

Women in Psychedelics Announces atai as Platinum Sponsors
ATAI Life Sciences N.V. Common Shares (ATAI)
atai Life Sciences Announces R&D Day Agenda
See More Headlines
Receive ATAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atai Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

ATAI Company Calendar

Last Earnings
11/15/2021
Today
12/01/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/29/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ATAI
Fax
N/A
Employees
87
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$24.80
High Stock Price Forecast
$50.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+603.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
4 Analysts

Profitability

Net Income
$-167,810,000.00
Pretax Margin
-34,066.04%

Debt

Sales & Book Value

Annual Sales
$20.38 million
Book Value
$1.78 per share

Miscellaneous

Free Float
123,079,000
Market Cap
$585.56 million
Optionable
Not Optionable
Beta
0.51

Key Executives

  • Mr. Christian AngermayerMr. Christian Angermayer (Age 44)
    Founder & Chairman of the Supervisory Board
    Comp: $37.53k
  • Mr. Florian Brand (Age 35)
    Co-founder & CEO
    Comp: $627.77k
  • Dr. Srinivas G. Rao M.D. (Age 53)
    Ph.D., Co-Founder & Chief Scientific Officer
    Comp: $693.46k
  • Dr. Rolando Gutierrez-Esteinou M.D. (Age 61)
    Chief Medical Officer
    Comp: $615.38k
  • Mr. Gregory L. Weaver CPAMr. Gregory L. Weaver CPA (Age 66)
    M.B.A., Non-Employee Advisor
  • Mr. Stephen B. Bardin (Age 32)
    MD & CFO
  • Ms. Anne Johnson
    Chief Accounting Officer
  • Ms. Madison Crawford
    Sr. Mang. of Accounting
  • Mr. Aaqil Anwar
    Mang. of Corp. Fin. & Investor Relations
  • Mr. Ryan Barrett
    Sr. VP, Gen. Counsel & Company Sec.













ATAI Stock - Frequently Asked Questions

Should I buy or sell Atai Life Sciences stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atai Life Sciences in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ATAI shares.
View ATAI analyst ratings
or view top-rated stocks.

What is Atai Life Sciences' stock price forecast for 2023?

4 Wall Street research analysts have issued 1-year price objectives for Atai Life Sciences' shares. Their ATAI share price forecasts range from $9.00 to $50.00. On average, they anticipate the company's stock price to reach $24.80 in the next year. This suggests a possible upside of 602.5% from the stock's current price.
View analysts price targets for ATAI
or view top-rated stocks among Wall Street analysts.

How have ATAI shares performed in 2022?

Atai Life Sciences' stock was trading at $7.63 on January 1st, 2022. Since then, ATAI shares have decreased by 53.7% and is now trading at $3.53.
View the best growth stocks for 2022 here
.

When is Atai Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023.
View our ATAI earnings forecast
.

How were Atai Life Sciences' earnings last quarter?

Atai Life Sciences (NASDAQ:ATAI) issued its quarterly earnings data on Monday, November, 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.28) by $0.07. The firm earned $0.27 million during the quarter.

What other stocks do shareholders of Atai Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Atai Life Sciences investors own include Alphabet (GOOG), Baidu (BIDU), Costco Wholesale (COST), MannKind (MNKD), NVIDIA (NVDA), Schlumberger (SLB), Twitter (TWTR), Adobe (ADBE), Allergan (AGN) and Achaogen (AKAO).

When did Atai Life Sciences IPO?

(ATAI) raised $200 million in an IPO on Friday, June 18th 2021. The company issued 14,300,000 shares at $13.00-$15.00 per share. Credit Suisse, Citigroup, Cowen and Berenberg served as the underwriters for the IPO and Cantor, RBC Capital Markets and Canaccord Genuity were co-managers.

What is Atai Life Sciences' stock symbol?

Atai Life Sciences trades on the NASDAQ under the ticker symbol "ATAI."

Who are Atai Life Sciences' major shareholders?

Atai Life Sciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (3.70%), BlackRock Inc. (0.93%), Two Sigma Investments LP (0.45%), Vanguard Group Inc. (0.29%), Credit Suisse AG (0.20%) and Two Sigma Advisers LP (0.15%). Insiders that own company stock include Apeiron Investment Group Ltd, Christian Angermayer, Gregory L Weaver and Srinivas Rao.
View institutional ownership trends
.

How do I buy shares of Atai Life Sciences?

Shares of ATAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Atai Life Sciences' stock price today?

One share of ATAI stock can currently be purchased for approximately $3.53.

How much money does Atai Life Sciences make?

Atai Life Sciences (NASDAQ:ATAI) has a market capitalization of $585.54 million and generates $20.38 million in revenue each year. The company earns $-167,810,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis.

How can I contact Atai Life Sciences?

Atai Life Sciences' mailing address is c/o Mindspace Krausenstra sse 9-10, Berlin, Berlin 10117. The official website for the company is www.atai.net.cn. The company can be reached via phone at 617-699-5876 or via email at amytung@atai.net.cn.

This page (NASDAQ:ATAI) was last updated on 12/1/2022 by MarketBeat.com Staff